Multicenter, double-blind, placebo-controlled crossover study to assess the acute prokinetic efficacy of nizatidine-controlled release (150 and 300 mg) in patients with gastroesophageal reflux disease.

@article{McCallum2010MulticenterDP,
  title={Multicenter, double-blind, placebo-controlled crossover study to assess the acute prokinetic efficacy of nizatidine-controlled release (150 and 300 mg) in patients with gastroesophageal reflux disease.},
  author={Richard W. McCallum and E. Zarling and Allen C Goetsch and Carl W. Griffin and Irene Sarosiek and Reza A. Hejazi and Ralph T. Doyle and Keith S Rotenberg},
  journal={The American journal of the medical sciences},
  year={2010},
  volume={340 4},
  pages={
          259-63
        }
}
INTRODUCTION The aim of the study is to test whether nizatidine delivered via a unique bimodal pulsatile-controlled release system, nizatidine controlled release (CR), accelerates gastric emptying in patients with gastroesophageal reflux disease (GERD). METHODS Combined data were analyzed on 39 patients with delayed gastric emptying (DGE) from 2 studies (n = 84) assessing the prokinetic effect of nizatidine CR. A single-blind placebo baseline was followed by double-blind nizatidine CR (150… CONTINUE READING
1
Twitter Mention